Upon the completion of analysis of the final results of NORSE EIGHT, Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) application for ONS-5010 in the first quarter of ...
Earlier results from a short 28-day study showed promising weight loss outcomes with good tolerability, supporting the potential success of the ongoing trial ... a positive outlook for Viking ...
The recent update on the CORAL Phase 2b trial for Haduvio in treating chronic cough associated with idiopathic pulmonary fibrosis (CC-IPF) revealed a stable sample size, indicating confidence in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback